Change search
ReferencesLink to record
Permanent link

Direct link
Cost-effectiveness of resuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events
AstraZeneca LP, Wilmington, DE, USA.
AstraZeneca, Lund, Sweden.
Strategic HealthCare Solution, Monkton, MD, USA.
Medical Decision Modeling Inc, Indianapolis, IN, USA.
Show others and affiliations
2012 (English)In: ClinicoEconomics and Outcomes Research, ISSN 1178-6981, Vol. 4, 1-11 p.Article in journal (Refereed) Published
Abstract [en]

Background: To assess the long-term cost-effectiveness of rosuvastatin therapy compared with generic simvastatin and generic atorvastatin in reducing the incidence of cardiovascular events and mortality in a Swedish population with Framingham risk ≥20%.

Methods: A probabilistic Monte Carlo simulation model based on data from JUPITER (the Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) was used to estimate the long-term cost-effectiveness of rosuvastatin 20 mg daily versus simvastatin or atorvastatin 40 mg for the prevention of cardiovascular death and morbidity. The three-stage model included cardiovascular event prevention simulating the 4 years of JUPITER, initial prevention beyond the trial, and subsequent cardiovascular event prevention. A Swedish health care payer perspective (direct costs only) was modeled for a lifetime horizon, with 2008/2009 as the costing period. Univariate and probabilistic sensitivity analyses were performed.

Results: The incremental cost per quality-adjusted life-year (QALY) gained with rosuvastatin 20 mg over simvastatin or atorvastatin 40 mg ranged from SEK88,113 (rosuvastatin 20 mg versus simvastatin 40 mg; Framingham risk ≥30%; net avoidance of 34 events/1000 patients) to SEK497,542 (versus atorvastatin 40 mg: Framingham risk ≥20%; net avoidance of 11 events/1000 patients) over a lifetime horizon. Probabilistic sensitivity analyses indicated that at a willingness-to-pay threshold of SEK500,000/QALY, rosuvastatin 20 mg would be cost-effective for approximately 75%–85% of simulations relative to atorvastatin or simvastatin 40 mg. Sensitivity analyses indicated the findings to be robust.

Conclusion: Rosuvastatin 20 mg is cost-effective over a lifetime horizon compared with generic simvastatin or atorvastatin 40 mg in patients at high cardiovascular risk in Sweden.

Place, publisher, year, edition, pages
Dove Medical Press , 2012. Vol. 4, 1-11 p.
Keyword [en]
cardiovascular disease, cost-benefit analysis, cost-effectiveness, rosuvastatin, simvastatin, atorvastatin, generic, high risk
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-88576DOI: 10.2147/CEOR.S26621PubMedID: 22347800OAI: diva2:604936
Available from: 2013-02-12 Created: 2013-02-12 Last updated: 2014-10-31

Open Access in DiVA

fulltext(383 kB)266 downloads
File information
File name FULLTEXT01.pdfFile size 383 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Olsson, Anders
By organisation
Internal MedicineFaculty of Health SciencesDepartment of Endocrinology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 266 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 117 hits
ReferencesLink to record
Permanent link

Direct link